Format

Send to

Choose Destination
Nat Rev Drug Discov. 2006 Sep;5(9):723-9. Epub 2006 Aug 18.

Can open-source R&D reinvigorate drug research?

Author information

1
Bernard Munos is at Eli Lilly & Co., Lilly Corporate Center, 1085, Indianapolis, Indiana 46285, USA. bhmunos@stanfordalumni.org

Abstract

The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry?

PMID:
16915233
DOI:
10.1038/nrd2131
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center